Detected ·
Crystalys Therapeutics
$130M—
Crystalys Therapeutics closed a $130M Series B financing to advance global clinical development of dotinurad, a next-generation oral URAT1 inhibitor for the treatment of gout, including ongoing Phase 3 RUBY and TOPAZ studies.
- Website
- crystalystx.com
- Amount
- $130 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-02 12:02:49 UTC
- Signal ID
- cf18d4d8-e889-4d57-9000-4977580922ad
As the API returns it
{
"id": "cf18d4d8-e889-4d57-9000-4977580922ad",
"created_at": "2026-08-02T12:02:49.764947Z",
"company_name": "Crystalys Therapeutics",
"company_website_url": "crystalystx.com",
"company_linkedin_url": "https://www.linkedin.com/company/crystalys-therapeutics",
"event_type": "funding",
"funding_amount": 130000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Crystalys Therapeutics closed a $130M Series B financing to advance global clinical development of dotinurad, a next-generation oral URAT1 inhibitor for the treatment of gout, including ongoing Phase 3 RUBY and TOPAZ studies.*"
}